Earnings anticipation and leadership change at Kenvue

Kenvue (KVUE) is back in focus as investors look ahead to its upcoming first quarter earnings release, with recent profit forecasts and a key finance leadership change drawing fresh attention to the stock.

On April 10, 2026, the company named current Chief Accounting Officer Heather Howlett as interim Chief Financial Officer, effective May 12, 2026. This move places an experienced insider in the principal financial officer role during this transition period.

Kenvue’s recent share price has been relatively steady, with a 1 day share price return of 1.04% and a year to date share price return of 0.98%. However, the 1 year total shareholder return of negative 19.82% points to weaker longer term outcomes. The upcoming earnings release and CFO transition are now key reference points for how investors reassess both growth potential and risk.

If this kind of earnings focused story has your attention, it could be a good moment to broaden your watchlist with 17 top founder-led companies

With Kenvue trading at a discount to analyst price targets and with recent returns still under pressure, the key question is whether this setup signals an undervalued consumer health stock or a market that is already pricing in future growth.

Most Popular Narrative: 30.3% Undervalued

According to the most followed narrative on Kenvue, the fair value sits at $25.09 compared with the latest close of $17.49. This sets up a clear valuation gap for investors to consider, especially with earnings and leadership changes on the horizon.

With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business. Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue’s brands.

Curious what sits behind that higher fair value, according to julio and the narrative model. The story leans on steadier growth, richer margins and a premium earnings multiple that assumes these brands keep earning their shelf space.

Result: Fair Value of $25.09 (UNDERVALUED)

However, this story can break if rising input costs force sharper price hikes that push shoppers to private labels, or if talc related reputational damage lingers longer than expected.

Another view on valuation

The most popular narrative sees Kenvue as 30.3% undervalued on a fair value of $25.09, but the current P/E of 22.8x tells a tougher story. It sits higher than the global personal products industry at 19.9x, the peer average at 18.2x and even above a 19.9x fair ratio the market could move toward. That gap raises a simple question for you: is this a margin of safety, or a sign the market wants more proof first?

Next Steps

With mixed signals on value and sentiment, this is a moment to move fast, cross check the data, and weigh both sides of the story, starting with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Kenvue has sharpened your focus, now is the time to widen the lens and spot other opportunities before they move out of reach.

• Target potential mispricings by scanning 54 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores that score well on financial strength and risk metrics.
• Hunt for future standouts with the screener containing 23 high quality undiscovered gems that the market may not be paying full attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.